$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000168316823007911 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$7.680M	$5.958M	$132.8K
YoY Change	94.94%	4385.93%	163.61%
Cost Of Revenue	$5.112M	$3.967M	$65.78K
YoY Change	108.77%	5931.06%	237.18%
Gross Profit	$2.568M	$1.990M	$67.03K
YoY Change	72.22%	2869.42%	117.12%
Gross Profit Margin	33.44%	33.41%	50.47%
Selling, General & Admin	$2.897M	$3.012M	$1.422M
YoY Change	-54.06%	111.83%	371.58%
% of Gross Profit	112.79%	151.32%	2121.18%
Research & Development	$816.3K	$238.0K	$362.5K
YoY Change	1854.81%	-34.34%	62.94%
% of Gross Profit	31.79%	11.96%	540.84%
Depreciation & Amortization	$39.15K	$37.21K	$789.00
YoY Change	106.38%	4616.1%	-75.27%
% of Gross Profit	1.52%	1.87%	1.18%
Operating Expenses	$3.755M	$3.250M	$362.5K
YoY Change	-42.47%	796.45%	-31.23%
Operating Profit	-$1.187M	-$779.5K	-$1.718M
YoY Change	-76.43%	-54.63%	246.19%
Interest Expense	$157.5K	$38.53K	$2.00
YoY Change	86.12%	1926250.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net		$168.9K	$261.0K
YoY Change		-35.26%
Pretax Income	-$1.030M	-$610.5K	-$1.457M
YoY Change	-95.58%	-58.1%	-63.93%
Income Tax	$220.3K	$40.95K	$0.00
% Of Pretax Income
Net Earnings	-$1.250M	-$651.5K	-$1.457M
YoY Change	-94.68%	-55.29%	-63.93%
Net Earnings / Revenue	-16.28%	-10.94%	-1097.09%
Basic Earnings Per Share		$0.04	-$0.08
Diluted Earnings Per Share	-$5.25	-$0.03	-$77.15K
COMMON SHARES
Basic Shares Outstanding	25.68M shares	25.75M shares	18.89M shares
Diluted Shares Outstanding		25.69M shares	18.89M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.29M	$18.85M	$40.56M
YoY Change	-25.35%	-53.52%	1599.31%
Cash & Equivalents	$16.29M	$18.85M	$40.56M
Short-Term Investments
Other Short-Term Assets	$310.6K	$40.00K	$34.98K
YoY Change	9.44%	14.35%	7.17%
Inventory	$5.735M	$4.517M	$269.6K
Prepaid Expenses	$310.6K	$37.56K	$27.39K
Receivables	$2.552M	$2.034M	$22.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.89M	$25.43M	$40.86M
YoY Change	-8.87%	-37.75%	1539.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.013M	$334.9K	$3.770K
YoY Change	156.86%	8783.87%	-63.15%
Goodwill	$0.00
YoY Change
Intangibles	$1.444M	$1.216M
YoY Change	85.91%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.457M	$2.215M	$3.770K
YoY Change	27.2%	58664.59%	-63.18%
TOTAL ASSETS
Total Short-Term Assets	$24.89M	$25.43M	$40.86M
Total Long-Term Assets	$2.457M	$2.215M	$3.770K
Total Assets	$27.35M	$27.65M	$40.86M
YoY Change	-6.49%	-32.34%	1533.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.585M	$2.221M	$480.2K
YoY Change	-7.75%	362.48%	747.08%
Accrued Expenses	$118.7K	$120.0K	$0.00
YoY Change	-3.54%		-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.552M	$5.088M	$480.2K
YoY Change	-19.9%	959.56%	1.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$539.0K	$560.0K
YoY Change	-16.07%
Total Long-Term Liabilities	$539.0K	$598.7K	$0.00
YoY Change	-21.34%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.552M	$5.088M	$480.2K
Total Long-Term Liabilities	$539.0K	$598.7K	$0.00
Total Liabilities	$6.140M	$5.687M	$480.2K
YoY Change	-19.39%	1084.23%	-86.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$63.91M	-$62.66M	-$35.89M
YoY Change	7.59%	74.59%
Common Stock	$28.02K	$25.68K	$18.89K
YoY Change	24.08%	35.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.21M	$21.96M	$40.38M
YoY Change
Total Liabilities & Shareholders Equity	$27.35M	$27.65M	$40.86M
YoY Change	-6.49%	-32.34%	1533.32%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$1.250M	-$651.5K	-$1.457M
YoY Change	-94.68%	-55.29%	-63.93%
Depreciation, Depletion And Amortization	$39.15K	$37.21K	$789.00
YoY Change	106.38%	4616.1%	-75.27%
Cash From Operating Activities	-$2.685M	-$460.0K	-$1.124M
YoY Change	19.52%	-59.07%	87.04%
INVESTING ACTIVITIES
Capital Expenditures	$308.1K	$10.00K
YoY Change	1.02%
Acquisitions
YoY Change
Other Investing Activities	$31.95K	$30.00K
YoY Change	-100.22%
Cash From Investing Activities	-$266.2K	$20.00K
YoY Change	-98.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-34.41K	-60.00K	0.000
YoY Change	-98.36%		-100.0%
NET CHANGE
Cash From Operating Activities	-2.685M	-460.0K	-1.124M
Cash From Investing Activities	-266.2K	20.00K
Cash From Financing Activities	-34.41K	-60.00K	0.000
Net Change In Cash	-2.986M	-500.0K	-1.124M
YoY Change	-84.25%	-55.51%	-266.51%
FREE CASH FLOW
Cash From Operating Activities	-$2.685M	-$460.0K	-$1.124M
Capital Expenditures	$308.1K	$10.00K
Free Cash Flow	-$2.993M	-$470.0K
YoY Change	17.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001402328
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q3	SBFM	Repurchase Stock RepurchaseStock		usd
	SBFM	Repurchase Of Common Stock RepurchaseOfCommonStock		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41282
	dei	Entity Registrant Name EntityRegistrantName	SUNSHINE BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5566275
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6500 Trans-Canada Highway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Pointe-Claire
	dei	Entity Address City Or Town EntityAddressCityOrTown	Quebec
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	H9R 0A5
	dei	City Area Code CityAreaCode	(514)
	dei	Local Phone Number LocalPhoneNumber	426-6161
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25678290	shares
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18846140	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2034119	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1912153	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	4517044	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3289945	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	37556	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	283799	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	25434859	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27312334	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	334922	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394249	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1216207	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	776856	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	664296	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	760409	usd
CY2023Q3	us-gaap	Assets Assets	27650284	usd
CY2022Q4	us-gaap	Assets Assets	29243848	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2220870	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2802797	usd
CY2023Q3	SBFM	Earnout Payable EarnoutPayable	2547831	usd
CY2022Q4	SBFM	Earnout Payable EarnoutPayable	3632000	usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	201541	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	373191	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	117840	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123026	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5088082	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6931014	usd
CY2023Q3	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	555687	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642232	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	598719	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	685264	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5686801	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7616278	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25678290	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25678290	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22585632	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22585632	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	25678	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22585	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84387890	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80841752	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	204549	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	161847	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62655634	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59399614	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	21963483	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27650284	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29243848	usd
CY2023Q3	us-gaap	Revenues Revenues	5957668	usd
CY2022Q3	us-gaap	Revenues Revenues	132808	usd
	us-gaap	Revenues Revenues	16412586	usd
	us-gaap	Revenues Revenues	405760	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3967412	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	65783	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10641461	usd
	us-gaap	Cost Of Revenue CostOfRevenue	200311	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1990256	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	67025	usd
	us-gaap	Gross Profit GrossProfit	5771125	usd
	us-gaap	Gross Profit GrossProfit	205449	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	56350	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	122913	usd
	us-gaap	Professional Fees ProfessionalFees	301381	usd
	us-gaap	Professional Fees ProfessionalFees	237773	usd
CY2023Q3	SBFM	Consulting Expense ConsultingExpense	221781	usd
CY2022Q3	SBFM	Consulting Expense ConsultingExpense	162852	usd
	SBFM	Consulting Expense ConsultingExpense	745850	usd
	SBFM	Consulting Expense ConsultingExpense	270033	usd
CY2023Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2022Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	300000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	133302	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	146467	usd
	us-gaap	Legal Fees LegalFees	392874	usd
	us-gaap	Legal Fees LegalFees	403386	usd
CY2023Q3	us-gaap	Marketing Expense MarketingExpense	241897	usd
CY2022Q3	us-gaap	Marketing Expense MarketingExpense	217666	usd
	us-gaap	Marketing Expense MarketingExpense	502987	usd
	us-gaap	Marketing Expense MarketingExpense	400386	usd
CY2023Q3	SBFM	Office Expense OfficeExpense	544215	usd
CY2022Q3	SBFM	Office Expense OfficeExpense	76818	usd
	SBFM	Office Expense OfficeExpense	1422058	usd
	SBFM	Office Expense OfficeExpense	449730	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	238012	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	362500	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1039502	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	770095	usd
CY2023Q3	us-gaap	Salaries And Wages SalariesAndWages	1144377	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	595000	usd
	us-gaap	Salaries And Wages SalariesAndWages	4344801	usd
	us-gaap	Salaries And Wages SalariesAndWages	1105000	usd
CY2023Q3	SBFM	Taxes Taxes	52586	usd
CY2022Q3	SBFM	Taxes Taxes	0	usd
	SBFM	Taxes Taxes	212953	usd
	SBFM	Taxes Taxes	0	usd
CY2023Q3	us-gaap	Depreciation Depreciation	37210	usd
CY2022Q3	us-gaap	Depreciation Depreciation	789	usd
	us-gaap	Depreciation Depreciation	106797	usd
	us-gaap	Depreciation Depreciation	6186	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2769730	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1785005	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9369203	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3842589	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-779474	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1717980	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3598078	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3637140	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	40	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-206	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45	usd
CY2023Q3	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	207431	usd
CY2022Q3	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	260938	usd
	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	624361	usd
	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	406984	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	38527	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	2	usd
	us-gaap	Interest Expense InterestExpense	107198	usd
	us-gaap	Interest Expense InterestExpense	12866	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	168944	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	260961	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	516957	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	405015	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-610530	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1457019	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3081121	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3232125	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40952	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	174899	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-651482	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1457019	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3256020	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3232125	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-460507	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-45126	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	42702	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-56764	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1111989	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1502145	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3213318	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3288889	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.133
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25690449	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25690449	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18885632	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18885632	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24507122	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24507122	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12789733	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12789733	shares
	us-gaap	Net Income Loss NetIncomeLoss	-3256020	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3232125	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	106794	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6186	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	374	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-45	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	118482	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7776	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1221112	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	163991	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-247977	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2235	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-587973	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	437267	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-172076	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1084169	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-48287	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6085435	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3001746	usd
	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	97498	usd
	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19804	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	464614	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-386920	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4089218	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43560363	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1156	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	541143	usd
	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	99000	usd
	SBFM	Payment For Lease Liability PaymentForLeaseLiability	93125	usd
	SBFM	Payment For Lease Liability PaymentForLeaseLiability	-0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1900000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3456106	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41561363	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3016249	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	38559617	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-105617	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	35952	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56764	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18846140	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40555931	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	61151	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23109793	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1111989	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	21963483	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4089218	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1156	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3213318	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	21963483	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41886280	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1502145	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	40384135	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
	SBFM	Common Stock And Prefunded Warrants Issued In Public Offering CommonStockAndPrefundedWarrantsIssuedInPublicOffering	30367185	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13193177	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	99000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3288889	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	40384135	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	55418	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	54240	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	15599	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7370	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14758115	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	7927165	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-26192503	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-2224253	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-26164764	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12289655	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1233570	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	13905	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1247475	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31268	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1216207	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	776856	usd
	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	470619	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1247475	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31268	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1216207	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10797	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26746	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	55418	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000	usd
	us-gaap	Dividends Dividends	0	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	664296	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	117840	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	555687	usd
	SBFM	Lessee Operating Lease Remaining Lease Term1 LesseeOperatingLeaseRemainingLeaseTerm1	6 years 3 months
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	30124	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	116090	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	116277	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	110134	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	103736	usd
CY2023Q3	SBFM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	197166	usd
CY2023Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	245000	usd
CY2022Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	362500	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1290000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	770095	usd
CY2023Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	300000	usd
CY2022Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2683	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2683	pure

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001683168-23-007911-index-headers.html	Edgar Link	pending
0001683168-23-007911-index.html	Edgar Link	pending
0001683168-23-007911.txt	Edgar Link	pending
0001683168-23-007911-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20230930.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshinelogo.jpg	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10q-093023.htm	Edgar Link	pending
sbfm-20230930_def.xml	Edgar Link	unprocessable
sbfm-20230930_cal.xml	Edgar Link	unprocessable
sbfm-20230930_lab.xml	Edgar Link	unprocessable
sbfm-20230930_pre.xml	Edgar Link	unprocessable
sunshine_i10q-093023_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2023 Q4 Form 10-Q Financial Statement

#000168316823007911 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2023 Q4 Form 10-Q Financial Statement

#000168316823007911 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm